ISSN: 1859 - 2872
Blood group B can be a predictor of the EGFR mutations in patients with lung adenocarcinoma
Main Article Content
Keywords
Tóm tắt
Background: The relationship between ABO blood and EGFR mutations in lung adenocarcinoma is still unclear. The purpose of this study was to evaluate the association between ABO blood and EGFR mutations percentage in patients with lung adenocarcinoma. Subject and method: A cross-sectional descriptive study, 276 lung adenocarcinoma patients were tested for EGFR mutations and ABO blood from January 2021 to March 2023. The relationship between the ratio of EGFR mutations with ABO blood and clinical, paraclinical characteristics was analyzed univariate and multivariate. Result: Median age of patients was 64 years old, male/female ratio was 3.5/1 and 73.6% of patients had a history of smoking. The percentage of EGFR mutations was 34.8%. Blood group O accounted for the highest percentage with 50%, followed by group B with 25% and group A 21%, only 4% of patients with group AB. Univariate analysis showed that the rate of EGFR mutations in patients with group B was 23.2%, lower than the rate of EGFR mutations in patients with non-B group, the difference was statistically significant with p=0.02. There was no association between groups O, A and AB with the ratio of EGFR mutations (p>0.05). Female and smoking history were also two factors associated with the ratio of EGFR mutations in univariate analysis. However, multivariate analysis showed that only female and non-B blood were the two independent factors associated with the EGFR mutations with OR = 3.4, p=0.037 and OR = 2.07, p=0.03, respectively. Conclusion: Blood group B can be a prognostic factor for the EGFR mutations in patients with lung adenocarcinoma. Further studies need to be conducted to further elucidate the prognostic role of ABO blood in lung cancer patients.
Article Details
Các tài liệu tham khảo
2. Aird I, Bentall HH, Roberts JA (1953) A relationship between cancer of stomach and the ABO blood groups. Br. Med. J 1(4814): 799-801.
3. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat. Genet 41(9): 986-990.
4. Ashley DJ (1969) Blood groups and lung cancer. J. Med. Genet 6(2): 183-186.
5. Urun Y, Utkan G, Cangir AK et al (2013) Association of ABO blood group and risk of lung cancer in a multicenter study in Turkey. Asian Pac. J. Cancer Prev 14(5): 2801-2803.
6. Oguz A, Unal D, Tasdemir A et al (2013) Lack of any association between blood groups and lung cancer, independent of histology. Asian Pac. J. Cancer Prev 14(1): 453-456.
7. Zappa C, Mousa SA (2016) Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res 5(3): 288-300.
8. Carpenter GM, King LJr, Cohen S (1978) Epidermal growth factor stimulates phosphorylation in membrane preparations in vitro. Nature 276: 409- 410.
9. Siegelin MD and Borczuk AC (2014) Epidermal growth factor receptor mutations in lung adenocarcinoma. Laboratory invertigation 94: 129-137.
10. Zhang YL, Yuan JQ, Wang KF et al (2016) The prevalence of EGFR mutation in patients with non-small cell lung cancer: A systematic review and meta-analysis. Oncotarrget 7(48): 78985-78993.
11. Shi Y, Au JSK, Thongprasert S et al (2014) A Prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small cell lung cancer of adenocarcinoma histology (PIONEER). Journal of Thoracic Oncology 9(2): 154-162.
12. Gürbüz M, Akkuş E, Karaalioğlu B et al (2021) Association between blood type and epidermal growth factor receptor mutation positivity in lung adenocarcinoma patients. J Oncol Sci 7(1): 20-24.
13. Shigematsu H, Lin L, Takahashi T et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Journal of the National Cancer Institute 97(5): 339-346.
14. Melosky B, Kambartel K, Häntsche M et al (2022) Worldwide prevalence of epidermal growth factor receptor mutations in non‑small cell lung cancer: A meta‑analysis. Molecular Diagnosis & Therapy 26: 7-18.
15. Dang ATH, Tran VU, Tran TT et al (2020) Actionable Mutation Profiles of non-small cell Lung cancer patients from Vietnamese population. Scientific RepoRtS 10: 2707.
16. Kuijpers CCHJ, Hendriks LEL, Derks JL et al (2018) Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-Squamous non-small cell lung cncer. Lung cancer 121: 76-81.
17. Racial and ethnic distribution of ABO blood types. Bloodbook.com. Archived from the original on 4 March 2010. Retrieved 1 August 2010.